TP53 and acute lymphoblastic leukemia: Hendy et al. identified TP53 mutations in 13% of newly diagnosed children with ALL, 10.3% of those in complete remission (CR), and 17.6% of the relapsed group, demonstrating a significant difference between these groups [341].